S&P 500   4,272.53 (-1.50%)
DOW   33,626.40 (-1.12%)
QQQ   353.37 (-1.74%)
AAPL   171.79 (-2.44%)
MSFT   310.23 (-2.30%)
META   299.44 (-0.46%)
GOOGL   128.20 (-2.22%)
AMZN   125.42 (-4.46%)
TSLA   243.92 (-1.24%)
NVDA   418.49 (-0.88%)
NIO   8.40 (+0.60%)
BABA   85.81 (-1.62%)
AMD   95.44 (-1.99%)
T   15.01 (-0.33%)
F   12.42 (-1.27%)
MU   67.68 (-1.31%)
CGC   0.91 (-3.61%)
GE   110.05 (-1.49%)
DIS   80.02 (-1.22%)
AMC   7.90 (-2.95%)
PFE   32.47 (-1.55%)
PYPL   58.78 (-0.14%)
NFLX   377.75 (-1.83%)
S&P 500   4,272.53 (-1.50%)
DOW   33,626.40 (-1.12%)
QQQ   353.37 (-1.74%)
AAPL   171.79 (-2.44%)
MSFT   310.23 (-2.30%)
META   299.44 (-0.46%)
GOOGL   128.20 (-2.22%)
AMZN   125.42 (-4.46%)
TSLA   243.92 (-1.24%)
NVDA   418.49 (-0.88%)
NIO   8.40 (+0.60%)
BABA   85.81 (-1.62%)
AMD   95.44 (-1.99%)
T   15.01 (-0.33%)
F   12.42 (-1.27%)
MU   67.68 (-1.31%)
CGC   0.91 (-3.61%)
GE   110.05 (-1.49%)
DIS   80.02 (-1.22%)
AMC   7.90 (-2.95%)
PFE   32.47 (-1.55%)
PYPL   58.78 (-0.14%)
NFLX   377.75 (-1.83%)
S&P 500   4,272.53 (-1.50%)
DOW   33,626.40 (-1.12%)
QQQ   353.37 (-1.74%)
AAPL   171.79 (-2.44%)
MSFT   310.23 (-2.30%)
META   299.44 (-0.46%)
GOOGL   128.20 (-2.22%)
AMZN   125.42 (-4.46%)
TSLA   243.92 (-1.24%)
NVDA   418.49 (-0.88%)
NIO   8.40 (+0.60%)
BABA   85.81 (-1.62%)
AMD   95.44 (-1.99%)
T   15.01 (-0.33%)
F   12.42 (-1.27%)
MU   67.68 (-1.31%)
CGC   0.91 (-3.61%)
GE   110.05 (-1.49%)
DIS   80.02 (-1.22%)
AMC   7.90 (-2.95%)
PFE   32.47 (-1.55%)
PYPL   58.78 (-0.14%)
NFLX   377.75 (-1.83%)
S&P 500   4,272.53 (-1.50%)
DOW   33,626.40 (-1.12%)
QQQ   353.37 (-1.74%)
AAPL   171.79 (-2.44%)
MSFT   310.23 (-2.30%)
META   299.44 (-0.46%)
GOOGL   128.20 (-2.22%)
AMZN   125.42 (-4.46%)
TSLA   243.92 (-1.24%)
NVDA   418.49 (-0.88%)
NIO   8.40 (+0.60%)
BABA   85.81 (-1.62%)
AMD   95.44 (-1.99%)
T   15.01 (-0.33%)
F   12.42 (-1.27%)
MU   67.68 (-1.31%)
CGC   0.91 (-3.61%)
GE   110.05 (-1.49%)
DIS   80.02 (-1.22%)
AMC   7.90 (-2.95%)
PFE   32.47 (-1.55%)
PYPL   58.78 (-0.14%)
NFLX   377.75 (-1.83%)
NASDAQ:GILD

Gilead Sciences (GILD) Competitors

$75.56
+0.73 (+0.98%)
(As of 03:34 PM ET)
Compare
Today's Range
$75.32
$76.27
50-Day Range
$73.94
$80.67
52-Week Range
$61.44
$89.74
Volume
3.35 million shs
Average Volume
5.74 million shs
Market Capitalization
$94.15 billion
P/E Ratio
17.37
Dividend Yield
3.97%
Price Target
$90.05

GILD vs. AMGN, SGEN, BIIB, MRNA, ARGX, BNTX, VRTX, REGN, ELV, and CI

Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Amgen (AMGN), Seagen (SGEN), Biogen (BIIB), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Elevance Health (ELV), and The Cigna Group (CI). These companies are all part of the "medical" sector.

Gilead Sciences vs.

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.

Amgen has lower revenue, but higher earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$27.28B3.46$4.59B$4.3517.44
Amgen$26.32B5.46$6.55B$14.8318.10

Gilead Sciences pays an annual dividend of $3.00 per share and has a dividend yield of 4.0%. Amgen pays an annual dividend of $8.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 69.0% of its earnings in the form of a dividend. Amgen pays out 57.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Gilead Sciences currently has a consensus price target of $90.05, suggesting a potential upside of 19.09%. Amgen has a consensus price target of $265.44, suggesting a potential downside of 0.85%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.50
Amgen
2 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Amgen had 10 more articles in the media than Gilead Sciences. MarketBeat recorded 21 mentions for Amgen and 11 mentions for Gilead Sciences. Amgen's average media sentiment score of 0.92 beat Gilead Sciences' score of 0.82 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
7 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Amgen
13 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Amgen has a net margin of 30.02% compared to Gilead Sciences' net margin of 20.03%. Amgen's return on equity of 196.60% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences20.03% 37.53% 12.66%
Amgen 30.02%196.60%12.42%

82.3% of Gilead Sciences shares are owned by institutional investors. Comparatively, 74.4% of Amgen shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.6% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Gilead Sciences has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Gilead Sciences received 942 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.74% of users gave Gilead Sciences an outperform vote while only 72.80% of users gave Amgen an outperform vote.

CompanyUnderperformOutperform
Gilead SciencesOutperform Votes
2438
77.74%
Underperform Votes
698
22.26%
AmgenOutperform Votes
1496
72.80%
Underperform Votes
559
27.20%

Summary

Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.


Get Gilead Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GILD vs. The Competition

MetricGilead SciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$94.51B$2.60B$4.40B$6.22B
Dividend Yield4.00%2.25%5.80%9.76%
P/E Ratio17.444.06116.2711.65
Price / Sales3.46126.512,837.7955.32
Price / Cash8.3525.1021.4522.67
Price / Book4.493.454.524.68
Net Income$4.59B$55.42M$123.05M$185.53M
7 Day Performance0.11%-4.24%-1.62%-2.59%
1 Month Performance-1.31%-6.05%-3.29%-4.51%
1 Year Performance21.67%19.98%11.02%6.13%

Gilead Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMGN
Amgen
3.1308 of 5 stars
$264.31
+0.4%
$265.44
+0.4%
+17.6%$141.38B$26.32B17.8225,200
SGEN
Seagen
1.5885 of 5 stars
$208.31
+0.6%
$190.47
-8.6%
+54.8%$39.10B$1.96B-53.553,256Analyst Report
News Coverage
BIIB
Biogen
2.832 of 5 stars
$256.67
+1.3%
$325.36
+26.8%
+28.9%$37.17B$10.17B13.978,725News Coverage
Positive News
MRNA
Moderna
2.601 of 5 stars
$106.74
+2.5%
$155.52
+45.7%
-20.6%$39.63B$10.52B39.393,900
ARGX
argenx
1.7088 of 5 stars
$524.13
+0.2%
$506.71
-3.3%
+48.2%$30.68B$445.27M-73.10843Gap Down
BNTX
BioNTech
2.1487 of 5 stars
$110.43
+1.3%
$158.69
+43.7%
-19.7%$26.61B$18.24B6.194,530
VRTX
Vertex Pharmaceuticals
2.4109 of 5 stars
$358.26
+1.8%
$367.04
+2.5%
+23.7%$92.47B$8.93B27.664,800Positive News
REGN
Regeneron Pharmaceuticals
2.1999 of 5 stars
$836.76
+1.5%
$904.00
+8.0%
+19.7%$90.84B$12.17B22.1211,851News Coverage
Positive News
ELV
Elevance Health
3.7647 of 5 stars
$438.67
-0.9%
$568.46
+29.6%
+0.0%$103.37B$156.60B16.43102,300Positive News
CI
The Cigna Group
2.9498 of 5 stars
$284.64
-0.2%
$339.11
+19.1%
+6.0%$84.25B$180.52B12.9671,300

Related Companies and Tools

This page (NASDAQ:GILD) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -